Recent News & Events

  • HiTS Seminar: Bissan Al-Lazikani, PhD, 10:00 am, Tuesday, March 20, 2018 March 15, 2018 - Bissan Al-Lazikani, PhD Head of Data Science, Institute of Cancer Research, UK   Integrative Big Data for Cancer Drug Discovery and Individualised Therapy Advances in technology are enabling unprecedented systematic mapping of disease mechanisms. To fully exploit this wealth of knowledge in advancing cancer therapy, we must develop integrative ‘Big Knowledge’ approaches to inform drug […]
  • HiTS Seminar: Neal Rosen, MD, PhD, 11:00 am, Thursday, February 8, 2018 February 1, 2018 - Neal Rosen, MD, PhD Memorial Sloan Kettering Cancer Center Mutant Allele-specific Oncoprotein Function – Basic and Translational Implications 11:00 am – 12:00 pm Thursday, February 8, 2018 Harvard Medical School 200 Longwood Avenue Warren Alpert Bldg, 5th Floor, Room 563 Boston, MA 02115
  • Combination Rethink: “Bet Hedging” Explains the Efficacy of Many Combination Cancer Therapies December 14, 2017 - Benefits of many cancer drug combinations not due to interactions between drugs, but to a form of bet hedging At a glance: Survival benefits of many cancer drug combinations are not due to drug synergy, but to a form of “bet hedging.” Combination treatment gives each patient multiple chances of responding to at least one […]
  • HiTS Seminar: Juliet Williams and Hui Gao, 10:00 am, November 16, 2017 November 2, 2017 - Juliet Williams, Ph.D. and Hui Gao, Ph.D. Novartis Institutes of Biomedical Research 10:00 am – 11:00 am Thursday, November 16, 2017 Harvard Medical School 200 Longwood Avenue Warren Alpert Bldg, Room 563 Human Clinical Trials in Mice: Modeling Inter-patient Response Heterogeneity in PDXs Less than 10% of molecules which enter oncology trials become approved drugs. […]